Skip to main content

Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.

Publication ,  Journal Article
Kemeny, HR; Elsamadicy, AA; Farber, SH; Champion, CD; Lorrey, SJ; Chongsathidkiet, P; Woroniecka, KI; Cui, X; Shen, SH; Rhodin, KE; Tsvankin, V ...
Published in: Clin Cancer Res
March 1, 2020

PURPOSE: Although pituitary adenoma is classified as benign, Cushing disease is associated with significant morbidity due to the numerous sequelae of elevated cortisol levels. Successful therapy for Cushing disease remains elusive due to high rates of treatment-refractory recurrence. The frequent emergence of lymphocytic hypophysitis following checkpoint blockade for other cancers, as well as the expression of PD-L1 on pituitary adenomas, suggest a role for immunotherapy. EXPERIMENTAL DESIGN: This study confirms PD-L1 expression on functioning pituitary adenomas and is the first to evaluate the efficacy of checkpoint blockade (anti-PD-L1) therapy in a preclinical model of Cushing disease. RESULTS: Herein, treatment with anti-PD-L1 was successful in reducing adrenocorticotropic hormone plasma levels, decreasing tumor growth, and increasing survival in our model. Furthermore, tumor-infiltrating T cells demonstrated a pattern of checkpoint expression similar to other checkpoint blockade-susceptible tumors. CONCLUSIONS: This suggests that immunotherapy, particularly blockade of the PD1/PD-L1 axis, may be a novel therapeutic option for refractory Cushing disease. Clinical investigation is encouraged.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

March 1, 2020

Volume

26

Issue

5

Start / End Page

1141 / 1151

Location

United States

Related Subject Headings

  • Young Adult
  • T-Lymphocytes
  • Survival Rate
  • Pituitary Neoplasms
  • Pituitary ACTH Hypersecretion
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice, Inbred C57BL
  • Mice
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kemeny, H. R., Elsamadicy, A. A., Farber, S. H., Champion, C. D., Lorrey, S. J., Chongsathidkiet, P., … Fecci, P. E. (2020). Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res, 26(5), 1141–1151. https://doi.org/10.1158/1078-0432.CCR-18-3486
Kemeny, Hanna R., Aladine A. Elsamadicy, S Harrison Farber, Cosette D. Champion, Selena J. Lorrey, Pakawat Chongsathidkiet, Karolina I. Woroniecka, et al. “Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.Clin Cancer Res 26, no. 5 (March 1, 2020): 1141–51. https://doi.org/10.1158/1078-0432.CCR-18-3486.
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, et al. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2020 Mar 1;26(5):1141–51.
Kemeny, Hanna R., et al. “Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.Clin Cancer Res, vol. 26, no. 5, Mar. 2020, pp. 1141–51. Pubmed, doi:10.1158/1078-0432.CCR-18-3486.
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, Woroniecka KI, Cui X, Shen SH, Rhodin KE, Tsvankin V, Everitt J, Sanchez-Perez L, Healy P, McLendon RE, Codd PJ, Dunn IF, Fecci PE. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2020 Mar 1;26(5):1141–1151.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

March 1, 2020

Volume

26

Issue

5

Start / End Page

1141 / 1151

Location

United States

Related Subject Headings

  • Young Adult
  • T-Lymphocytes
  • Survival Rate
  • Pituitary Neoplasms
  • Pituitary ACTH Hypersecretion
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice, Inbred C57BL
  • Mice
  • Male